CLLS · NASDAQ · Biotechnology

Cellectis (ADR) (CLLS)

Develops gene-edited allogeneic CAR-T candidates and manufacturing capabilities.

$1.56
After hours−0.01 (−0.64%)
At close$1.57(+3.97%)